Clinical characteristics and correlation analysis of IVIG resistance in children with kawasaki disease complicated with hip synovitis: case-control study

Objective To investigate the clinical characteristics and risk factors of Kawasaki disease (KD) complicated with hip synovitis. Methods Children with KD admitted from January 1, 2011, to December 31, 2020, in the KD database of Yuying Children's Hospital Affiliated with Wenzhou Medical University were retrospectively included. We selected KD children with hip synovitis as the case group and KD children without hip synovitis as the control group to analyze the possible risk factors of hip synovitis in KD children. Results Among 2,871 KD children admitted to our center in recent years, 28 had hip synovitis. In this study 140 KD children were enrolled, including 28 KD children with hip synovitis and 112 children with general KD (within one month of admission). The onset age of KD patients with hip synovitis was 30.92 (23.23–49.99) months, and there were 17 cases of bilateral hip involvement. The course of synovitis (limited movement, joint pain, lameness, unwillingness to stand, etc.) ranged from 1 to 19 days, with an average of (8.8 ± 4.6) days. We treated all KD children with IVIG (Intravenous immunoglobulin) plus aspirin, among which five patients in the case group developed coronary artery damage, six acquired IVIG resistance, and synovial inflammation disappeared within two weeks. Age, weight, length of stay, and incidence of IVIG resistance significantly differed between the two groups (P = 0.001, 0.005, <0.001, and 0.035, respectively). Logistic regression analysis showed that KD combined with hip synovitis was an independent risk factor for developing propyl pellet resistance, with an OR value of 4.625 (95% CI: 1.095, 19.526). Conclusion KD combined with hip synovitis mainly involves bilateral hip joints, and joint pain and limited movement are the main clinical features. The symptoms are mild and self-limiting. KD combined with hip synovitis is a risk factor for IVIG resistance. Hip synovitis is a good predictor of IVIG resistance.

[1]  D. Rigante,et al.  An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children , 2023, Diagnostics.

[2]  Chieh‐Mao Chuang,et al.  Impact of Kawasaki disease on juvenile idiopathic arthritis in real-world patients: A population-based cohort study , 2022, Frontiers in Immunology.

[3]  E. Ota,et al.  Monoclonal antibody and anti-cytokine biologics for Kawasaki disease: A systematic review and meta-analysis. , 2021, Seminars in arthritis and rheumatism.

[4]  H. Takada,et al.  Overlapping Features in Kawasaki Disease-Related Arthritis and Systemic-Onset Juvenile Idiopathic Arthritis: A Nationwide Study in Japan , 2021, Frontiers in Pediatrics.

[5]  J. Chaturvedi,et al.  Pancytopenia and transient synovitis of hip joint in a SARS CoV-2 positive pregnant female: a case report , 2021, International Journal of Reproduction, Contraception, Obstetrics and Gynecology.

[6]  Y. Hua,et al.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?—Current evidence based on a meta-analysis , 2021, PloS one.

[7]  Surjit Singh,et al.  Kawasaki disease: characteristics, diagnosis, and unusual presentations , 2019, Expert review of clinical immunology.

[8]  Fei Liu,et al.  Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm , 2019, Clinical and Experimental Medicine.

[9]  K. Kusuhara,et al.  Kawasaki disease‐related arthritis with synovial involvement , 2018, Pediatrics international : official journal of the Japan Pediatric Society.

[10]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[11]  Yuehua Wu,et al.  TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[12]  W. C. Allen,et al.  Incomplete Kawasaki disease presenting as bilateral hip synovitis , 2017, Journal of paediatrics and child health.

[13]  B. McCrindle,et al.  Inositol-Triphosphate 3-Kinase C Mediates Inflammasome Activation and Treatment Response in Kawasaki Disease , 2016, The Journal of Immunology.

[14]  J. Burns,et al.  Adjunctive therapies for Kawasaki disease. , 2016, The Journal of infection.

[15]  Nathan Timm,et al.  An Atypical Presentation of Atypical Kawasaki Disease , 2014, Pediatric emergency care.

[16]  Z. Du,et al.  Novel Predictors of Intravenous Immunoglobulin Resistance in Chinese Children with Kawasaki Disease , 2013, The Pediatric infectious disease journal.

[17]  M. Alomar,et al.  Transient synovitis of the hip as a complication of chickenpox in infant: Case study. , 2012, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[18]  K. Kotani,et al.  Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2009–2010 Nationwide Survey , 2012, Journal of epidemiology.

[19]  J. Gerring.  A case study , 2011, Technology and Society.

[20]  Francis Berenbaum,et al.  The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis , 2010, Nature Reviews Rheumatology.

[21]  B. Koes,et al.  Acute non-traumatic hip pathology in children: incidence and presentation in family practice. , 2010, Family practice.

[22]  K. Kavaklı,et al.  Long‐term evaluation of radioisotope synovectomy with Yttrium 90 for chronic synovitis in Turkish haemophiliacs: Izmir experience , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  K. Nishigaki,et al.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[24]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[25]  J. Carlin,et al.  A randomized clinical trial: should the child with transient synovitis of the hip be treated with nonsteroidal anti-inflammatory drugs? , 2002, Annals of emergency medicine.

[26]  D. Sherry,et al.  Initial intravenous gammaglobulin treatment failure in Kawasaki disease. , 2000, Pediatrics.

[27]  M. Lequin,et al.  Anterior joint capsule of the normal hip and in children with transient synovitis: US study with anatomic and histologic correlation. , 1999, Radiology.

[28]  D. Heinegård,et al.  Transient synovitis of the hip in the child: Increased levels of proteoglycan fragments in joint fluid , 1987, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[29]  G. Schett,et al.  Interleukin-1 function and role in rheumatic disease , 2016, Nature Reviews Rheumatology.

[30]  J. Wardle,et al.  Sleep and nighttime energy consumption in early childhood: a population‐based cohort study , 2015, Pediatric obesity.

[31]  A. Yachie,et al.  Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease , 2014, Rheumatology International.

[32]  JCSJointWorkingGroup.  Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[33]  D. C. Henckel,et al.  Case report. , 1995, Journal.